Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma

NCT02337946 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Carcinoma

Interventions

DRUG: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
DRUG: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab

Sponsor

Takeda